2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% | | 企业授权产品 | 12% | | 研发收入 | 1% | 股价相对大盘走势 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p t . 信达生物 (01801.HK) 买进（Buy） 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 ...

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/12/10 | 21 ...

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p ...

Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% from the current price [11]. Core Insights - The company is focusing on enhancing its competitive edge by deploying high-end production capacity, with a significant investment of RMB 500 million in a new high-end pet staple food project in Shandong, expected to be completed by mid-2027 [11]. - The gross margin is projected to improve due to an increase in the proportion of high-end products, with gross margins expected to be 32.6%, 36.8%, and 42.3% from 2022 to 2024, respectively [11]. - The company is establishing a global production capacity layout, with projects in New Zealand and Thailand, aiming for a revenue target of RMB 9.65 billion by 2027 [11]. Financial Summary - The company’s net profit is forecasted to grow from RMB 709 million in 2025 to RMB 992 million in 2027, representing year-on-year growth rates of 13.5%, 19.1%, and 17.4% respectively [11]. - Earnings per share (EPS) are expected to increase from RMB 1.77 in 2025 to RMB 2.48 in 2027, with corresponding price-to-earnings (P/E) ratios of 36x, 30x, and 26x [11]. - Revenue projections show an increase from RMB 6.56 billion in 2025 to RMB 9.69 billion in 2027, reflecting the company's growth strategy and market positioning [14].

Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% from the current price [5][9]. Core Insights - The company is expected to achieve a net profit of between RMB 270 million and RMB 320 million in 2025, representing a year-on-year increase of 55% to 84%. The fourth quarter of 2025 is projected to show a turnaround with a net profit of RMB 20 million to RMB 70 million [5]. - The company has implemented significant reforms, leading to improved operational efficiency and a reduction in sales expense ratio by over 30% year-on-year. This has resulted in a marginal improvement in business operations [8]. - For 2026, the company anticipates continued operational improvements, with stable growth in its raw materials business and a positive trend in its medical terminal products, which saw a 14.5% year-on-year revenue increase in Q3 2025 [8]. Financial Summary - The company forecasts net profits of RMB 310 million, RMB 530 million, and RMB 600 million for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 76.4%, 72%, and 13.3% [8]. - Earnings per share (EPS) are projected to be RMB 0.64, RMB 1.10, and RMB 1.24 for the same years, with corresponding price-to-earnings (P/E) ratios of 70, 41, and 36 [8]. - The company's revenue is expected to be RMB 4.895 billion in 2025, with a gradual increase to RMB 5.980 billion by 2027 [11].

2026 年 2 月 2 日 | 何利超 | | --- | | H70529@capital.com.tw | | 目标价(元) 750 | 公司基本资讯 | 产业别 | | 通信 | | --- | --- | --- | | A 股价(2026/1/30) | | 649.00 | | 深证成指(2026/1/30) | | 14205.89 | | 股价 12 个月高/低 | | 658.8/66.86 | | 总发行股数(百万) | | 1111.12 | | A 股数(百万) | | 1105.50 | | A 市值(亿元) | | 7174.70 | | 主要股东 | | 山东中际投资 | | | | 控股有限公司 | | | | (10.93%) | | 每股净值(元) | | 23.75 | | 股价/账面净值 | | 27.33 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | 6.4 | 32.4 545.8 | | 近期评等 | | | | 2025.11.06 | 买进 | 496.88 | | 2025.07.16 | 买进 | 174.81 | | 2025.04 ...

Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% from the current price [5][9]. Core Insights - The company is expected to achieve a net profit of between RMB 270 million and RMB 320 million in 2025, representing a year-on-year increase of 55% to 84%. The fourth quarter of 2025 is projected to show a turnaround with a net profit of RMB 20 million to RMB 70 million [5]. - The company has implemented significant reforms, leading to improved operational efficiency and a reduction in sales expense ratio by over 30% year-on-year. This has resulted in a marginal improvement in business operations [8]. - For 2026, the company anticipates continued operational improvements, with stable growth in its raw materials business and a positive trend in its medical terminal products, which saw a 14.5% year-on-year revenue increase in Q3 2025 [8]. Financial Summary - The company forecasts net profits of RMB 310 million, RMB 530 million, and RMB 600 million for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 76.4%, 72%, and 13.3% [8]. - Earnings per share (EPS) are projected to be RMB 0.64, RMB 1.10, and RMB 1.24 for the same years, with corresponding price-to-earnings (P/E) ratios of 70, 41, and 36 [8]. - The company's revenue is expected to decline to RMB 4.895 billion in 2025 before recovering to RMB 5.315 billion in 2026 and RMB 5.980 billion in 2027 [11].

2026 年 2 月 2 日 何利超 H70529@capital.com.tw 目标价(元) 500 公司基本资讯 | 产业别 | | 通信 | | --- | --- | --- | | A 股价(2026/1/30) | | 419.49 | | 深证成指(2026/1/30) | | 14205.89 | | 股价 12 个月高/低 | | 468.81/46.7 | | 总发行股数(百万) | | 994.01 | | A 股数(百万) | | 885.42 | | A 市值(亿元) | | 3714.24 | | 主要股东 | | 黄晓雷 | | | | (07.12%) | | 每股净值(元) | | 14.61 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | -2.6 | 24.8 452.9 | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025.07.23 | 174.2 | 买进 | | 产品组合 | | | --- | --- | | 光通信 | 100% | | 机构投资者占流通 | A 股比例 | | | -- ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5]. Core Insights - The company is expected to achieve a significant increase in net profit for 2025, with estimates ranging from RMB 9.8 billion to RMB 11.8 billion, representing a year-on-year growth of 90% to 128% [6]. - The demand for computing power is driving the company's performance, with a notable increase in the shipment of high-speed optical modules and the introduction of new products like the 1.6T optical module [6][8]. - The company maintains its position as a global leader in the optical module sector, with strong technological advancements in 1.6T and silicon photonics [6]. Summary by Sections Company Overview - The company operates in the communication industry, with a current A-share price of RMB 649.00 and a market capitalization of RMB 71.75 billion [2]. - Major shareholders include Shandong Zhongji Investment Holding Co., Ltd. with a 10.93% stake [2]. Financial Performance - The company forecasts a net profit of RMB 11.26 billion for 2025, with a year-on-year growth of 117.8% [8]. - Revenue is projected to grow significantly, reaching RMB 36.5 billion in 2025 and RMB 58.6 billion in 2026 [10]. - The gross profit margin is expected to improve, with Q4 2025 showing a 30% increase in revenue and a 35% increase in gross profit [6]. Product and Market Position - The company is recognized as the global leader in the optical module market, with its 1.6T optical module product entering the testing phase and expected to start mass shipments in the second half of 2026 [6]. - The company has a strong technological foundation in silicon photonics, which is anticipated to enhance its competitive edge in the AI-driven market [6]. Earnings Forecast - The earnings per share (EPS) for 2025 is estimated at RMB 10.14, with a projected P/E ratio of 64 [8]. - The company expects to maintain robust growth in net profit through 2027, with estimates of RMB 20.13 billion and RMB 28.02 billion for 2026 and 2027, respectively [8].

2026 年 2 月 2 日 何利超 H70529@capital.com.tw 目标价(元) 500 公司基本资讯 | 产业别 | | 通信 | | --- | --- | --- | | A 股价(2026/1/30) | | 419.49 | | 深证成指(2026/1/30) | | 14205.89 | | 股价 12 个月高/低 | | 468.81/46.7 | | 总发行股数(百万) | | 994.01 | | A 股数(百万) | | 885.42 | | A 市值(亿元) | | 3714.24 | | 主要股东 | | 黄晓雷 | | | | (07.12%) | | 每股净值(元) | | 14.61 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | -2.6 | 24.8 452.9 | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025.07.23 | 174.2 | 买进 | | 产品组合 | | | --- | --- | | 光通信 | 100% | | 机构投资者占流通 | A 股比例 | | | -- ...